A life insurance applicant in a tier 3 town once waited days for a doctor, a treadmill and a lab slot before a policy could be issued. Cardiotrack, a Bengaluru healthtech company, now sends a technician to that applicant’s home with a handheld 12-lead ECG, and the company says a physician-signed report reaches WhatsApp in under 60 seconds.
That shift sits at the centre of Cardiotrack’s AI cardiac screening business. The company says it has recorded more than 3.66 lakh ECG screenings across 21 countries, and it now runs medical examinations for life and health insurers across India.
The heart problem India keeps underdiagnosing
Heart disease is India’s largest killer. A Global Burden of Disease study published in The Lancet Global Health found that cardiovascular disease caused 28.1% of all deaths in India in 2016, up from 15.2% in 1990.
Screening has not kept pace. Cardiologists cluster in metros, and a standard 12-lead ECG still needs a trained reader. Outside large cities, the gap between a test and a reliable interpretation can run into days.
Insurance feels the same strain. Before a high-value life policy is issued, insurers order a medical examination report (MER), often with an ECG or a treadmill test. Slow medicals delay policy issuance and push applicants to drop off midway.
How Cardiotrack’s AI cardiac screening works
Cardiotrack, the brand of Uber Diagnostics Private Limited, builds a stack of four connected products. Each one removes a step that used to need a specialist in the room.
Cardiotrack Pulse, the pocket ECG
Pulse is a handheld device that records all 12 ECG leads at the same time, along with pulse oximetry and blood pressure. A technician records a reading in under two minutes, and the device sends it over Bluetooth to an Android app, which uploads it to the cloud.
The company lists a CDSCO licence, IEC 60601 certification, EMI and EMC testing, and ISO 9001:2015 certification for its quality system. India’s medical device regulator, the Central Drugs Standard Control Organisation, licenses such devices.
Cardiotrack Reader, AI with a human check
Reader is the AI cardiac screening engine that interprets each ECG. The company says five separate models read each trace independently, and a consensus engine weighs their outputs. When the models disagree, the case goes to a doctor, and the report prints a confidence score.
According to Cardiotrack, its internal benchmarks on production cases show 93% sensitivity and 95% specificity, using a South Asian training set of more than five lakh ECGs. The company says about 80% of reports clear through AI and 20% go to human review. Reader also works on ECG machines that clinics already own.
Examiner and Ethos for insurers
Examiner turns the insurance medical examination into a spoken conversation in Indian languages. Ethos.AI, the operations layer, tracks each case from order to signed report and keeps an audit trail that underwriters can check later.
For applicants who need a stress test, the company uses a portable stepper at home in place of a treadmill. A 12-lead ECG streams live while a physician supervises over video.
Market timing for AI cardiac screening in insurance
Two numbers explain why insurers are paying attention. India’s life insurance penetration fell to 2.7% in FY25, according to the IRDAI annual report as reported in the press. Growing that base means reaching applicants in smaller towns, where medical infrastructure is thin.
Cardiotrack says 65% of the cases it handles come from tier 3 and tier 4 cities, and that more than 95% of medicals happen at the applicant’s home. Faster, home-based AI cardiac screening shortens the path from proposal to policy in exactly the markets insurers want to grow.
AI cardiac screening traction and proof points
Cardiotrack’s public numbers show a business operating at national scale. The company reports:
- More than 3.66 lakh ECG screenings, about 2.8 lakh of them in India
- 1,68,845 insurance medical cases handled
- More than 1.06 lakh physician-signed reports
- A network of 1,956 active labs across 832 cities and 13,511 PIN codes in 32 states and union territories
- 99% of reports closed within two days, and under four days end to end
Its recognition list includes the WHO Compendium of Innovative Health Technologies for low-resource settings, the NASSCOM League of 10, CNBC Young Turks, Intel and Startup Karnataka. The company has also filed two Indian patent applications, covering AI medical examination and validated AI ECG interpretation.
The founders behind Cardiotrack
Avin K. Agarwal and Ashim Roy started Uber Diagnostics in Bengaluru in 2014. Agarwal, the CEO, studied medical electronics at VIT and spent five years in the Netherlands before returning to India. He has received a Bill and Melinda Gates Foundation grant for healthcare work.
Roy studied at BITS Pilani, IIT Delhi and the University of Adelaide, worked in Australia, the US and Canada, and returned to India in 2007. His earlier work focused on technology for socio-economic development.
The pair shipped their first handheld ECG in 2015. In 2022, they moved the company towards pre-policy medicals for life insurers, which turned its AI cardiac screening technology into an insurance workflow business.
Why investors should watch Cardiotrack
The timing trigger. Insurers want to grow beyond metros, and a slow, clinic-based MER is a bottleneck in that push. Cardiotrack sells speed and reach at the exact point where policies stall.
The wedge. Most ECG device makers sell hardware. Cardiotrack combines a licensed device, an AI reader that works on third-party machines, and a case-management platform. That stack lets its AI cardiac screening business earn on every case, whichever machine records the trace.
The business model. Revenue comes from B2B work with insurers, labs and clinics. Each completed medical is a billable unit, so volume across 832 cities compounds into recurring case flow.
Capital so far. BioSpectrum reported in March 2024 that Cardiotrack raised $2 million in a pre-Series A round led by angel investor Girish Narasimhan, after an earlier $1.6 million angel round from a group of UHNIs.
The next proof point. An independent validation of the AI ECG accuracy figures would move them from internal benchmarks to published evidence. That milestone would strengthen the case with underwriters and support a larger institutional round.
Healthtech readers can also see how Deepaarogya is applying AI to hospital documentation and how Curium Life is bringing AI into surgery.
The bigger opportunity
Every insurance medical is also a heart check for someone who may never have had one. With AI cardiac screening running at insurance scale, Cardiotrack is building a cardiac record for India’s next hundred million policyholders, town by town. Visit Cardiotrack to see the platform.
FAQ
What is AI cardiac screening?
AI cardiac screening uses software to read ECG traces and flag possible heart problems, often with a doctor reviewing uncertain cases. Cardiotrack pairs a portable 12-lead ECG with AI interpretation and physician sign-off.
Who uses Cardiotrack?
Life and health insurers, diagnostic labs and clinics use Cardiotrack for insurance medicals, ECG interpretation and home-based heart screening across more than 800 Indian cities.
Is Cardiotrack’s ECG device approved in India?
The company says its Pulse device holds a CDSCO licence and IEC 60601 certification, and that its quality system is ISO 9001:2015 certified.